BioCryst Pharmaceuticals, Inc.

Healthcare · Biotechnology

Overall research band Above average

Quality Strong

Valuation Weak

Balance sheet Strong

Market confirmation Not available

One-minute company read

What this report can tell you now

What the company does

BioCryst Pharmaceuticals, Inc. is a biotechnology company headquartered in Durham, North Carolina, focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company markets two primary products: Peramivir injection (sold as RAPIVAB, RAPIACTA, and PERAMIFLU) for the treatment of acute uncomplicated influenza, and ORLADEYO, an oral serine protease inhibitor for managing hereditary angioedema. BioCryst's development pipeline includes BCX9930, an oral factor D inhibitor in Phase II trials for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor in Phase I for fibrodysplasia ossificans progressiva; and Galidesivir, an RNA dependent-RNA polymerase inhibitor in Phase I targeting various RNA viruses. The company generates revenue through product sales and strategic collaborations and in-license agreements with pharmaceutical companies, governmental agencies, and academic institutions.

The current research profile is Industrial Company. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC137.2%Model input; read with the evidence status and period context.

Operating margin39.0%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years53.6%Model input; read with the evidence status and period context.

FCF margin37.4%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.